Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Circadian, Investment Research Report by Analyst Available on Circadian Website (ASX:CIR)

Circadian Technologies (ASX:CIR; OTCQX:CKDXY) announced today that a commissioned reports by a leading healthcare analyst, Edison Investment Research based in London, was published last night and is a...read more

Circadian, Data positive published on performance of Cancers of Unknown Primary Diagnostic Test (ASX:CIR)

- Data shows diagnostic test capable of detecting primary source of cancers with high level of accuracy and specificity across 15 different tumour types. - Commercial launch expected March/April ...read more

Circadian, Operational Achievements and Half-Year Financial Report 31 December 2011 (ASX:CIR)

In accordance with Listing Rule 4.2A, attached is the Half-Year Financial Report (reviewed) on the consolidated results of Circadian Technologies Limited (‘Circadian’ or ‘Group&rs...read more

Circadian, Potential new therapy: VGX-100 identified for improving corneal graft survival (ASX:CIR)

- Data published in the scientific journal Investigative Ophthamology & Visual Science generated by investigators at The Schepens Eye Research Institute led by Harvard University Professor Reza...read more

BIOTECH SHOWCASE PARC 55, SAN FRANCISCO 11 JANUARY 2012 (ASX:CIR)

To view Presentation please download PDF below:

Circadian commences first Phase 1 clinical trial of VEGF-C antibody VGX-100 in cancer patients (ASX:CIR)

Melbourne, Australia January 9 2012 – Circadian Technologies Limited (ASX:CIR, OTCQX:CKDXY) announced today that it has commenced the first Phase 1 clinical trial of its fully human monoclona...read more

CEO on IND status for VGX-100 (ASX:CIR)

In this Open Briefing, CEO & MD Robert Klupacs discusses - Clinical and commercial implications of IND status for VGX-100 - Design, end points and time lines of Phase I trials - Outlook...read more

Circadian receives FDA IND approval to begin clinical trials with VGX-100 for the treatment of cancer patients with solid tumors (ASX:CIR)

Melbourne, Australia October 31, 2011 – Circadian Technologies Limited (ASX: CIR, OTCQX:CKDXY) announces that its 100% owned subsidiary, Vegenics Pty Ltd, has received approval for its invest...read more

Healthscope commences clinical validation study of Circadian’s Cancer Diagnostic (ASX:CIR)

Circadian Technologies Limited (ASX: CIR, OTCQX:CKDXY) announced today that Healthscope Limited, its licensee and development partner for a novel diagnostic technology for “Cancers of Unknown...read more

Retirements from Circadian Board of Directors (ASX:CIR)

Circadian announces today that Dr Jonathan Skipper has provided notice that he will retire as a director of the board effective 24 November 2011 at the Annual General Meeting (AGM) and that Mr Carl...read more

Circadian files IND with FDA for VGX-100 for the treatment of cancer patients with solid tumors (ASX:CIR)

Melbourne, Australia September 30, 2011 – Circadian Technologies Limited (ASX:CIR, OTCQX:CKDXY) is extremely proud to announce that its 100% owned subsidiary, Vegenics Pty Ltd, has submitted ...read more

VGX-100 identified as potential new therapy for Dry Eye Disease (ASX:CIR)

Melbourne, Australia September 13, 2011– Circadian Technologies Limited (ASX: CIR, OTCQX:CKDXY) announced today the publication of data in the scientific journal Archives of Ophthalmology sho...read more

Circadian makes key appointment in clinical trials management (ASX:CIR)

Circadian Technologies Limited (ASX:CIR, OTCQX:CKDXY) is pleased to announce that it has appointed Dr Ian Leitch to the newly created position of Director – Clinical Research effective from 1...read more

VEGF-C and VEGF-D identified as biomarkers for Avastin resistance in colorectal cancer patients (ASX:CIR)

- Data presented at American Society for Clinical Oncology (“ASCO”) Annual meeting in Chicago - Data obtained from 42 patients treated with chemotherapy (5-flourouracil and irinotecan...read more

Van Leeuwenhoeck Research (ASX:CIR)

Initiating Coverage Report 3. Technology Circadian is developing a variety of drugs to block the interaction between VEGF Receptor-3 (VEGFR-3) and its ligands VEGF-C and VEGF-D. Drugs...read more

Viewing: 1 - 15 of 18 Previous | Next